Longboard Pharmaceuticals (LBPH)
(Delayed Data from NSDQ)
$22.05 USD
+1.45 (7.01%)
Updated May 7, 2024 04:00 PM ET
After-Market: $22.07 +0.03 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Cash flow Statements
Fiscal Year End for Longboard Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -54.42 | -43.95 | -27.80 | -14.40 | NA |
Depreciation/Amortization & Depletion | 0.01 | 0.01 | 0.00 | 0.00 | NA |
Net Change from Assets/Liabilities | 1.27 | 3.12 | 0.97 | 2.45 | NA |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Operating Activities | 2.28 | 2.76 | 2.12 | 8.51 | NA |
Net Cash From Operating Activities | -50.87 | -38.06 | -24.71 | -3.44 | NA |
Property & Equipment | 0.00 | 0.00 | -0.02 | 0.00 | NA |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Investments | 24.23 | -17.06 | -40.70 | 0.00 | NA |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Cash from Investing Activities | 24.23 | -17.06 | -40.72 | 0.00 | NA |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 32.28 | 0.00 | 84.77 | 59.20 | NA |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Other Financing Activities | -2.09 | -0.44 | -8.32 | -0.44 | NA |
Net Cash from Financing Activities | 30.19 | -0.44 | 76.45 | 58.76 | NA |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | NA |
Net Change In Cash & Equivalents | 3.56 | -55.57 | 11.03 | 55.32 | NA |
Cash at Beginning of Period | 10.78 | 66.35 | 55.32 | 0.00 | NA |
Cash at End of Period | 14.33 | 10.78 | 66.35 | 55.32 | NA |
Diluted Net EPS | -2.39 | -2.56 | -1.93 | -3.78 | NA |
Fiscal Year End for Longboard Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -14.99 | -54.42 | -39.39 | -26.46 | -11.46 |
Depreciation/Amortization & Depletion | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | -0.09 | 1.27 | -2.27 | -1.27 | -2.34 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -0.10 | 2.28 | 1.82 | 1.17 | 0.70 |
Net Cash From Operating Activities | -15.18 | -50.87 | -39.84 | -26.55 | -13.10 |
Property & Equipment | 0.00 | 0.00 | 0.00 | -34.41 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -230.92 | 24.23 | 25.79 | 48.45 | 6.08 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -230.92 | 24.23 | 25.79 | 14.05 | 6.08 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 301.40 | 32.28 | 29.18 | 23.05 | 23.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -14.99 | -2.09 | -2.00 | -1.81 | -1.64 |
Net Cash from Financing Activities | 286.40 | 30.19 | 27.18 | 21.24 | 21.36 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 40.31 | 3.56 | 13.14 | 8.73 | 14.35 |
Cash at Beginning of Period | 14.33 | 10.78 | 10.78 | 10.78 | 10.78 |
Cash at End of Period | 54.64 | 14.33 | 23.91 | 19.50 | 25.12 |
Diluted Net EPS | -0.42 | -0.63 | -0.55 | -0.65 | -0.56 |